Letrozole and Infertility Among Males With Spermatogenic Failure: A Randomized Clinical Trial - Scorecard - MDSpire

Letrozole and Infertility Among Males With Spermatogenic Failure: A Randomized Clinical Trial

  • By

  • Yifan Sun

  • Chencheng Yao

  • Gang Liu

  • Zheng Li

  • Xiaoyu Yang

  • Qigui Chen

  • Zhen Ye

  • Honggang Li

  • Xiaowei Qu

  • Haibin Guo

  • Jun Yang

  • Tao Wang

  • Guoqing Liang

  • Xiaobin Zhu

  • Yichang Lu

  • Weikang Chen

  • Fengbin Zhang

  • Ruhui Tian

  • Erlei Zhi

  • Huirong Chen

  • Fujun Zhao

  • Furong Bai

  • Hongfang Sun

  • Jianxiong Zhang

  • Xinjie Bu

  • Dewei Qian

  • Sicheng Wu

  • Yan Qiu

  • Peng Li

  • June 18, 2026

  • 0 min

Share

Clinical Scorecard: Efficacy of Letrozole in Treating Male Infertility Due to Spermatogenic Failure: Results from a Randomized Clinical Study

At a Glance

CategoryDetail
ConditionSpermatogenic Failure (SPGF)
Key MechanismsAromatase inhibitors (AIs) like letrozole inhibit the conversion of testosterone to estradiol, relieving negative feedback on the hypothalamic-pituitary-gonadal axis.
Target PopulationMen aged 22 to 50 years with a diagnosis of SPGF, including azoospermia, cryptozoospermia, and severe oligozoospermia.
Care SettingMulticenter male infertility centers.

Key Highlights

  • Letrozole treatment may restore spermatogenesis in men with SPGF.
  • The study included a randomized, open-label design with blinded outcome assessment.
  • Primary endpoint was the upgrade rate in WHO Sperm Concentration Categories at 3 months.
  • Participants received letrozole plus vitamins or control vitamins only.
  • Exclusion criteria included bilateral reproductive tract obstruction and hypogonadotropic hypogonadism.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of SPGF confirmed by at least 2 separate semen analyses.

Management

  • Letrozole treatment for eligible men with SPGF.

Monitoring & Follow-up

  • Assessment of semen parameters and serum reproductive hormone levels at 3 months.

Risks

  • Exclusion of participants with severe systemic diseases or prior use of AIs.

Patient & Prescribing Data

Men with diagnosed SPGF aged 22 to 50 years.

Letrozole 2.5 mg once daily plus vitamin C and E for 3 months.

Clinical Best Practices

  • Conduct semen analyses according to WHO Laboratory Manual.
  • Monitor for adverse events and laboratory safety parameters during treatment.

Related Resources & Content

Original Source(s)

Letrozole and Infertility Among Males With Spermatogenic Failure: A Randomized Clinical Trial

  • by Yifan Sun, Chencheng Yao, Gang Liu, Zheng Li, Xiaoyu Yang, Qigui Chen, Zhen Ye, Honggang Li, Xiaowei Qu, Haibin Guo, Jun Yang, Tao Wang, Guoqing Liang, Xiaobin Zhu, Yichang Lu, Weikang Chen, Fengbin Zhang, Ruhui Tian, Erlei Zhi, Huirong Chen, Fujun Zhao, Furong Bai, Hongfang Sun, Jianxiong Zhang, Xinjie Bu, Dewei Qian, Sicheng Wu, Yan Qiu, Peng Li

  • June 18, 2026

Related Content

Albuminuria, but not eGFR, tracks diabetic retinopathy severity and retinal ischemia: population-based discovery, clinical replication, and OCTA evidence

Endometrial dysfunction in embryo implantation: from molecular mechanisms to clinical management

Short-term effect of oral glucose solution in older patients with hypoglycemia undergoing hemodialysis